Targets › PTH
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout May 2027.
Peptide hormone secreted by parathyroid chief cells that acts as a primary endocrine regulator of extracellular calcium and phosphate homeostasis, acting primarily on bone and kidney to maintain serum calcium levels within a narrow range. Acts by binding and activating the G protein-coupled receptor PTH1R, engaging the receptor to activate G(s)-mediated cAMP/PKA signaling and G(q)-mediated PLC/PKC signaling. (UniProt, P01270)
Open in Phaseline: the race on PTH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Extend Biosciences | EXT608 Modified parathyroid hormone attached to vitamin D to extend half-life | PTH | Phase 2 | Hypoparathyroidism | May 2027 |
Hypoparathyroidism (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.